Mizolastine is a new peripherally acting histamine H
1 receptor antagonist, which is metabolized by the liver both through conjugation and by cytochrome-P450 (CYP). It is reported that aging affects the pharmacokinetics of some drugs metabolized by the liver. Therefore, we performed a parallel group comparison of the pharmacokinetics of mizolastine in elderly and young subjects. The subjects were 12 apparently healthy male volunteers (6 elderly subjects aged 65 to 67 years and 6 younger subjects aged 20 to 24 years). Each subject was administered a tablet containing 10 mg of mizolastine at 9: 00 in the morning following an overnight fast. Blood sampling for the determination of plasma concentration of mizolastine was performed at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours after mizolastine administration. Mizolastine was well tolerated by the younger subjects, while symptoms such as sleepiness were noted by the elderly. The plasma concentration of mizolastine was higher in the elderly than in the young (p=0.010, a group effect by repeated measured ANOVA). The maximum plasma concentration (C
max) was higher in the elderly (283.8±44.0 vs 222.2±30.1 ng/ml: elderly vs young, mean±S. D., p=0.018 by t-test) and area under the curve for 24 hours (AUC (0→24 hr)) was also larger in the elderly (2308±472 vs 1527±398 ng·hr/ml, p=0.011). Although time to reach C
max was identical in the two groups, the elimination half life (t
1/2) was longer in the elderly (8.8±1.9 vs 6.4±1.3 hours, p=0.030). It is considered that a change in the dosage regimen is not needed in the elderly, as the increase in the plasma concentration among elder subjects was about 50%, however careful observation of the subjective symptoms is desirable since sleepiness was only found in the elderly.
抄録全体を表示